Moderna Says The European Commission Granted Marketing Authorization For Mresvia (Mrna-1345) To Protect Adults Aged 60 Years And Older From Lower Respiratory Tract Disease Caused By RSV Infection
Portfolio Pulse from Benzinga Newsdesk
Moderna announced that the European Commission has granted marketing authorization for its vaccine Mresvia (mRNA-1345) to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection.
August 23, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna received marketing authorization from the European Commission for its RSV vaccine, Mresvia, targeting adults aged 60 and older.
The approval of Mresvia by the European Commission is a significant regulatory milestone for Moderna, potentially boosting its market presence and revenue in the European market. This positive development is likely to have a favorable impact on Moderna's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90